SARS-CoV-2 Innate Effector Associations and Viral Load in Early Nasopharyngeal Infection - Liou, Theodore G; Adler, Frederick R; Cahill, Barbara C; Cox, David R; Cox, James E; Grant, Garett J; Hanson, Kimberly E; Hartsell, Stephen C; Hatton, Nathan D; Helms, My N; Jensen, Judy L; Kartsonaki, Christiana; et al. (medRxiv, 2020)
To examine innate immune responses in early SARS-CoV-2 infection that may change clinical outcomes, we compared nasopharyngeal swab data from 20 virus-positive and 20 virus-negative individuals. Multiple innate immune-related and ACE-2 transcripts increased with infection and were strongly associated with increasing viral load. We found widespread discrepancies between transcription and translation. Interferon proteins were unchanged or decreased in infected samples suggesting virally-induced shut-off of host anti-viral protein responses. However, IP-10 and several interferon-stimulated gene proteins increased with viral load. Older age was associated with modifications of some effects. Our findings may characterize the disrupted immune landscape of early disease.Competing Interest StatementTGL, JLS and KAP are supported by NIH/NHLBI R01 125520 and by the US Cystic Fibrosis Foundation, Bethesda, MD, grants LIOU13A0, LIOU14P0, LIOU14Y4, LIOU15Y4. During the course of the study, TGL, JLS and KAP received other support for performing cystic fibrosis-related clinical trials from Abbvie, Inc; Corbus Pharmaceuticals Holdings, Inc; Gilead Sciences, Inc.; Laurent Pharmaceuticals, Inc; Nivalis Therapeutics, Inc; Novartis Pharmaceuticals; Proteostasis Therapeutics, Inc; Savara, Inc; and Vertex Pharmaceuticals, Inc. None of the funding was provided for development of vaccines or treatments for SARS-CoV-2 infection. FRA received other support from the National Science Foundation (grant EMSW21-RTG). JEC is supported by NIH/NIDDK U54 DK110858 05. MNH is supported by NIH/NHLBI R01HL137033. CK received support from the UK Medical Research Council. DTL is supported by NIH/NAIAD R01AI130378. The sponsors of clinical trials and funders of other support played no roles in the current study.Funding StatementThis study was funded by the Ben B and Iris M Margolis Family Foundation of Utah and the Claudia Ruth Goodrich Stevens Endowment Fund at the University of Utah. This work was supported by the University of Utah Flow Cytometry Facility in addition to the National Cancer Institute through Award Number 5P30CA042014-24. Proteomics mass spectrometry analysis was performed at the Mass Spectrometry and Proteomics Core Facility at the University of Utah which is supported by U54 DK110858 05. Mass spectrometry equipment was obtained through a Shared Instrumentation Grant 1 S10 OD018210 01A1. Oligonucleotide primers were synthesized by the DNA/Peptide Facility, part of the Health Sciences Center Cores at the University of Utah.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Our project was reviewed at the University of Utah by both the Institutional Review Board and the Biosafety Committee. An exemption from informed consent was allowed because patient samples were de-identified.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe final data set used to generate all results is available upon request to the corresponding author. Samples are not available as most were consumed by the studies presented.